Immune Pharmaceuticals Ltd., a privately held Israeli company, and American EpiCept Corporation, announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013. The combined company, to be named Immune Pharmaceuticals, Inc., will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments